Image shown: Athersys' MultiStem therapy can improve the lives of millions of stroke victims.
We cover some very interesting technologies in this piece, from a nano-cap company that could best be described as a call option, a stroke therapy firm that may improve the lives of millions, to a big cap genomic sequencing leader that has exposure to the development of a liquid biopsy test for cancer.
This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!